Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Exon array analysis of the response to bevacizumab/erlotinib in advanced non-small cell lung cancer

ABSTRACT: In the current study, we used exon arrays and clinical samples from a previous trial (SAKK 19/05) to investigate the expression variations at the exon-level of 3 genes potentially playing a key role in modulating treatment response (EGFR, KRAS, VEGFA). Exon-level biomarkers for the response to targeted therapy bevacizumab/erlotinib were identified in patients with metastatic non-small cell lung cancer Multicenter, prospective, open-label, single-arm, phase II trial.

ORGANISM(S): Homo sapiens

SUBMITTER: Florent Baty 

PROVIDER: E-GEOD-37138 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml

Similar Datasets

Transcriptomics Exon array analysis of the response to bevacizumab/erlotinib in advanced non-small cell lung cancer
2013-07-30 | GSE37138 | GEO
Transcriptomics SCREENING STUDY TO IDENTIFY DIAGNOSTIC MARKERS FOR LUNG CANCER IN ENDOBRONCHIAL LINING FLUID
2011-12-31 | E-GEOD-27489 | biostudies-arrayexpress
Unknown Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma.
| S-EPMC8124338 | biostudies-literature
Unknown Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.
| S-EPMC3896238 | biostudies-literature
Unknown Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
| S-EPMC3018944 | biostudies-literature
Unknown Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab.
| S-EPMC6507446 | biostudies-literature
Transcriptomics Immuno-priming with bevacizumab: durvalumab plus bevacizumab after prolonged exposition to bevacizumab in breast cancer
2020-10-15 | GSE139050 | GEO
Unknown Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.
| S-EPMC4760665 | biostudies-literature
Unknown EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
| S-EPMC3769372 | biostudies-literature
Unknown Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis.
| S-EPMC10594499 | biostudies-literature